Carris N W, Ghushchyan V, Libby A M, Smith S M
Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL, USA.
Department of Economics, American University of Armenia,Yerevan, Armenia.
J Hum Hypertens. 2016 Mar;30(3):191-6. doi: 10.1038/jhh.2015.61. Epub 2015 Jun 18.
Little is known about the impact of treatment-resistant hypertension (TRH) on health-related quality of life (HrQoL). We aimed to compare HrQoL measures in adults with apparent TRH (aTRH) and non-resistant hypertension among nationally representative US Medical Expenditure Panel Survey data pooled from 2000 to 2011. Cohorts compared were adults with aTRH (⩾2 unique fills from ⩾4 antihypertensive classes during a year) versus non-resistant hypertension (those with hypertension not meeting the aTRH definition). Key outcomes were cohort differences in SF-12v2 physical component summary (PCS) and mental component summary (MCS) scores and disease-state utility using the SF-6D. Of 57 150 adults with hypertension, 2501 (4.4%) met criteria for aTRH. Persons with aTRH, compared with non-resistant hypertension, were older (mean, 68 vs 61 years), had a higher BMI (30.9 vs 29.7 kg m(-)(2)) and were more likely to be Black (20% vs 14%), but less likely to be female (46% vs 54%). Persons with aTRH, compared with non-resistant hypertension, had lower mean PCS scores (35.8 vs 43.2; P<0.0001), and utility (0.68 vs 0.74; P<0.0001), but similar MCS scores (49.1 vs 50.4). In multivariable-adjusted analyses, aTRH was associated with a 2.37 (95% CI 1.71 to 3.02) lower PCS score and 0.02 (95% CI 0.01 to 0.03) lower utility, compared with non-resistant hypertension. In conclusion, aTRH was associated with substantially lower HrQoL in physical functioning and health utility, but not in mental functioning, compared with non-resistant hypertension. The multivariable-adjusted reduction in physical functioning was similar in magnitude to previous observations comparing hypertension with no hypertension.
关于难治性高血压(TRH)对健康相关生活质量(HrQoL)的影响,人们所知甚少。我们旨在在美国国家医疗支出小组调查2000年至2011年汇总的具有全国代表性的数据中,比较明显难治性高血压(aTRH)成人与非难治性高血压成人的HrQoL指标。所比较的队列是患有aTRH的成人(一年中来自至少4种抗高血压药物类别、至少2次不同的配药记录)与非难治性高血压患者(高血压患者但不符合aTRH定义)。主要结局是队列在SF - 12v2身体成分汇总(PCS)和精神成分汇总(MCS)得分以及使用SF - 6D的疾病状态效用方面的差异。在57150名高血压成人中,2501人(4.4%)符合aTRH标准。与非难治性高血压患者相比,aTRH患者年龄更大(平均年龄分别为68岁和61岁),体重指数更高(30.9 vs 29.7kg/m²),更可能是黑人(20% vs 14%),但女性比例更低(46% vs 54%)。与非难治性高血压患者相比,aTRH患者的平均PCS得分更低(35.8 vs 43.2;P<0.0001),效用更低(0.68 vs 0.74;P<0.0001),但MCS得分相似(49.1 vs 50.4)。在多变量调整分析中,与非难治性高血压相比,aTRH与PCS得分降低2.37(95%可信区间1.71至3.02)以及效用降低0.02(95%可信区间0.01至0.03)相关。总之,与非难治性高血压相比,aTRH在身体功能和健康效用方面与显著更低的HrQoL相关,但在精神功能方面并非如此。多变量调整后身体功能的降低幅度与之前比较高血压患者和无高血压患者的观察结果相似。